ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025
Whole transcriptome analysis of peripheral blood mononuclear cells from de novo and drug-naive Parkinson's disease patients.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Integrative Analysis Identifies PANoptosis-Associated Molecular Patterns and Immune Alterations in Rat Cerebral Ischemic-Reperfusion Injury.Cellular and molecular neurobiology · 2026Article
- Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood-based biomarkers represent a highly convenient and minimally invasive method to improve the diagnosis of Parkinson's disease (PD), particularly at early stages. In this study, we present a comprehensive analysis of transcriptional changes in peripheral blood mononuclear cells (PBMCs) from de novo and drug-naive, recently diagnosed PD patients (n = 23) and healthy sex- and age-matched controls (n = 16). Whole-transcriptome analysis revealed differentially expressed genes (DEGs) in PBMCs from PD patients, including genes with immune-related functions such as CHI3L1, FAM198B, ID3, MDX1, and PROK2. Gene set enrichment analysis (GSEA) further identified alterations in immune pathways, including the IL-6/JAK/STAT3 signaling pathway and the complement cascade, associated with PD. We performed cross-validation using two independent whole-blood transcriptomic datasets from PD patients to assess the reproducibility and biological relevance of our findings. Both comparisons showed moderate but highly significant correlations in gene expression patterns. Overall, our results reveal robust and reproducible transcriptional alterations in PBMCs from early-stage PD patients, underscoring the contribution of immune dysregulation to PD pathogenesis. These findings support the potential of PBMC transcriptomics as a valuable platform for biomarker discovery in Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.